When is the expected release of cosentyx generics?

When does the Cosentyx patent expire?

The Cosentyx patent protecting the active ingredient secukinumab expires in 2026. The earliest possible launch of generics would therefore fall after that date.

How long will Cosentyx exclusivity last?

Cosentyx retains market exclusivity through regulatory protections beyond the compound patent. These additional layers of protection, including pediatric and orphan-drug extensions, push any generic entry later than 2026.

What are the first expected dates for Cosentyx biosimilars?

First-generation biosimilars are projected for late 2027 or 2028. Companies such as Sandoz, Samsung Bioepis, and Bio-Texas are already developing candidates.

Why are companies challenging this patent?

Multiple firms have filed paragraph IV certifications against Cosentyx patents, triggering litigation that may shorten or extend the expected launch window depending on court outcomes.

What happens if a generic enters early?

An at-risk launch before full patent resolution could subject the biosimilar maker to damages if the courts ultimately uphold the original patents.

Can biosimilars enter before patent expiry?

No. Current US law prevents generic or biosimilar entry before the listed patents expire or a court declares them invalid.